Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Other Operating Expenses (2020 - 2024)

Rani Therapeutics Holdings has reported Other Operating Expenses over the past 2 years, most recently at $3.7 million for Q4 2024.

  • Quarterly results put Other Operating Expenses at $3.7 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Sep 2025 was $3.7 million (changed N/A YoY), and the annual figure for FY2024 was $3.7 million, changed.
  • Other Operating Expenses for Q4 2024 was $3.7 million at Rani Therapeutics Holdings, up from -$34.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for RANI hit a ceiling of $3.7 million in Q4 2024 and a floor of -$34.0 million in Q4 2020.